---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125353"
form_type: "8-K"
ticker: "CATX"
cik: "0000728387"
company_name: "Perspective Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:27:37.188223+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Perspective Therapeutics Q3 net loss $15.1M ($0.21/share); cash $267.8M funds into mid-2026

## Summary
- Net loss from continuing and discontinued ops $15.1M vs $10.4M YoY; basic loss per share $0.21.
- Cash, equivalents and short-term investments $267.8M (Sep 30, 2024) vs $9.2M at Dec 31, 2023.
- R&D expense surged 114% to $12.0M; G&A expense up 56% to $7.0M; no product revenue.
- Phase 1/2a trials advancing: VMT-α-NET and VMT01; combo cohort with nivolumab open.
- Manufacturing capacity expanded: second cGMP facility in Somerset, NJ and three new buildings purchased.

## SEC filing metadata
- accession: 0000950170-24-125353
- form_type: 8-K
- ticker: CATX
- cik: 0000728387
- company_name: Perspective Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/728387/000095017024125353/0000950170-24-125353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/728387/000095017024125353/catx-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125353
- JSON: https://secwatch.observer/filing/0000950170-24-125353.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.